To explore the risk factors of thrombosis in patients with JAK2 V617F -mutated myeloproliferative neoplasms (MPNs), a cohort of 1537 Chinese patients with JAK2 V617F -mutated MPN was retrospectively analyzed. The Kaplan-Meier method and multivariate Cox analysis were used to study the risk factors of thrombosis in patients with JAK2 V617F -mutated MPN. Among the 1537 MPN patients, 931, 468, and 138 had polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF), respectively. The median follow-up time was 7 years (range 1-47), and 12.8% of patients (197/1537) died during this period. A total of 16.8% (259/1399) of PV and ET patients had secondary myelofibrosis, and 2.5% (38/1537) of patients developed acute myeloid leukemia (AML). Thrombotic events occurred in 43.9% (675/1537) of patients, among which 91.4% (617/675) were arterial thrombosis and 16.6% (112/675) were venous thrombosis. The number of thrombotic events in PV, ET, and PMF patients was 439 (47.2%), 197 (42.1%) and 39 (28.2%), respectively. The multivariate analysis indicated that age ≥60 years old, HCT ≥48%, at least one cardiovascular risk factor, a history of thrombosis, and JAK2 V617F allele burden (V617F%) ≥50% are risk factors for thrombosis in JAK2 V617F -mutated MPN. According to the results of the multivariate analysis, a risk model of thrombosis was established and comprised low-risk (0 points), intermediate-risk (1 points) and
| INTRODUCTION
Philadelphia chromosome-negative myeloproliferative neoplasms (MPNs) are chronic myeloproliferative diseases caused by clonal expansion of malignant hematopoietic stem/progenitor cells. MPNs mainly include polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF). 1 Thrombosis, leukemic transformation, and myelofibrotic transformation are critical complications of MPN and are highly common in patients with MPN. [2] [3] [4] [5] [6] Fatalities due to thrombosis account for 35%~70% of the total mortality rate of MPN, making it the most important risk factor affecting eventfree survival and overall survival (OS) of MPN patients. 7 Studies in the last decade have shown that JAK2/CALR/MPL gene mutations are the driver mutations in MPN. [8] [9] [10] Among those, the JAK2 V617F mutation is considered the most common driver mutation of MPN and is detected in 95% of PV patients and 60% of ET and PMF patients. 11 In this work, we analyzed the clinical features, disease progression, and survival status of 1573 MPN patients with JAK2 V617F mutation and explored the risk factors affecting thrombosis in patients with JAK2 V617F -mutated MPN.
| METHODS

| Patients
A cohort of 1537 patients with JAK2 V617F -mutated MPN from January 1981 to December 2018 at the Second Hospital of Tianjin Medical University and the Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences were selected for analysis. When patients were included, we rechecked their medical history and carefully reevaluated whether they met 2016 WHO diagnostic criteria. All the MPN patients included in this study were diagnosed according to the 2016 WHO diagnostic criteria. 1 All patients signed an informed consent form. This study was approved by the ethics committee of the Second Hospital of Tianjin Medical University and the Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences.
| Analysis of the JAK2 V617F mutation and JAK2 V617F allele burden
The JAK2 V617F mutation was detected by nested allelespecific polymerase chain reaction (PCR). The primers are as follows: P 2 5'-CCTCAGAACGTTGATGGCA-3', P 2r 5'-ATTGCTTTCCTTTTTCACAACA-3', P nf 5'-AGCATTTGG TTTTAAATTATGGAGTATATG-3', and P mr 5'-GTTTACTT ACTCTCGTCTCCACAAAA-3'. The PCR amplification conditions were as follows: 95°C for 5 minutes; 40 cycles of 95°C for 30 seconds, 54°C for 25 seconds, and 72°C for 30 seconds; and 72°C for 10 minutes. The PCR products were analyzed by 2.5% agarose gel electrophoresis under ultraviolet light. The products were 453 bp, 279 bp (JAK2 V617F mutant allele), and 229 bp (wild-type allele). The JAK2 V617F -positive samples determined by the above methods were detected by StepOne real-time quantitative PCR with the following primers: forward primer 5'-AAGCTTTCTCACAAGCATTTGGTTT-3', reverse primer 5'-AGAAAGGCATTAGAAAGCCTGTAGTT-3'; JAK2 V617F wild-type TaqMan probe VIC-5'-TCTCCACAGACACATAC-3'; and JAK2 V617F mutant TaqMan probe FAM-5'-TCCACAGAAACATAC-3'. The PCR conditions were the same as those listed above. The standard curve was drawn by mixing the JAK2 V617F mutant homozygote with MPN expressing wild-type JAK2 in different proportions, and the JAK2 V617F allele burden was calculated as follows: V617F% = JAK2 V617F mutant/ (JAK2 V617F mutant plus JAK2 V617F wild type).
| Group
According to the 2016 WHO diagnostic criteria, the patients were divided into PV, ET and PMF groups. Patients with JAK 2V617F -mutated MPN were also divided into two groups as follows: V617F% ≥50% and <50%. They were divided according to thromboembolic events into an arterial thrombosis group and a venous thrombosis group. Thromboembolic events in all the patients were verified by computerized tomography scan, magnetic resonance imaging, digital subtraction angiography, or color Doppler ultrasound, and further diagnosed by a specialist. Arterial thrombosis is mainly divided into acute coronary syndrome, cerebral vascular thrombosis, splenic thrombosis, peripheral artery, and other arterial thrombosis, whereas venous thrombosis is mainly divided into peripheral venous thrombosis, portal venous thrombosis, pulmonary venous thrombosis, cerebral venous sinus thrombosis, other venous thrombosis, etc Cardiovascular (CV) risk factors include hypertension, hyperlipidemia, diabetes, and smoking. The secondary myelofibrosis in patients with PV and ET were diagnosed according to the 2016 WHO diagnostic criteria. All the patients in this study underwent bone marrow biopsy and were diagnosed by 2 or 3 hematopathologists independently. Patients with PV, ET, and PMF were divided into risk groups by their respective prognostic scoring systems. ET uses IPSET(International Prognostic Score for ET), 12 and PMF uses DIPSS-Plus (Dynamic International Prognostic Scoring System). 13 
| Statistical analysis
The overall survival (OS) of MPN patients was defined as the time between the diagnosis of MPN and death or the last follow-up. Thrombosis-free, myelofibrosis (MF)-free and acute myeloid leukemia (AML)-free survival were defined as the time between the diagnosis and the occurrence of thrombosis, MF transformation and AML, respectively. By comparing the expected survival of a healthy Chinese population with age-sex matching, using the mortality rate of healthy Chinese as a reference, we calculated the standardized mortality ratio (SMR). The abnormal distribution data are described as the median (range (Table S1 ).
| Survival of JAK2 V617F -mutated
MPN patient
The median follow-up time for the 1537 patients with JAK2 V617F -mutated MPN was 7 years (1 to 47 years). The .20], P < .0001) ( Figure 1A ). For patients with JAK2 V617F -mutated MPN with different diagnoses, the OS of PMF patients was significantly worse than that of PV and ET patients; ET patients had the best OS ( Figure 1B ). patients with V617F% ≥50% who did not develop thrombosis (P < .0001). The incidence of thrombosis was different in patients with different grades of bone marrow fibrosis (P = .002) and was higher in patients with bone marrow fibrosis grade 1 or 2 than in patients with higher grade fibrosis ( Table 2 ). The incidence of arterial thrombosis (91.4%, 617 patients) was significantly higher than that of venous thrombosis (16.6%, 112 patients). Cerebrovascular accidents (73.6%) were the main cause of arterial thrombosis. The incidence of thrombosis at the time of diagnosis or before diagnosis was 63.9% (431/675), and 52.4% (354/675) of patients still developed thrombosis after diagnosis. A total of 33.1% (223/675) of patients experienced two or more thrombotic events ( Table 1 ).
| Characteristics of thrombosis in patients with JAK2 V617F -mutated MPN
The overall incidence of thrombosis in patients with PV and ET was higher than that in patients with PMF (P < .0001, P = .003), and the incidence of thrombosis was higher in PV (62.9%) and ET (69%) patients at or before diagnosis; however, more thrombosis occurred in PMF (64.1%) patients after diagnosis. Furthermore, PMF had the highest incidence of splenic infarction (17.1%) ( Table 1) .
To establish a prognostic model, we selected the cutoff value determined by the ROC curve and applied it to conduct a univariate analysis for continuous variables such as HCT, white blood cell count, and platelet count. The indicators with statistical significance in the univariate analysis (age ≥60 years, male, HCT ≥48%, white blood cell count ≥10 × 10 9 /L, platelet count ≥ 475 × 10 9 /L, at least one CV risk factor, reticular fibers, history of thrombosis, and V617F% ≥50%) were included in NO thrombosis(n = 862) (Table S3 ).
Based on the results of the multivariable analysis, a predictive model was devised with the following risk factors: age ≥60 years old, at least one CV risk factor, history of thrombosis, and V617F% ≥50%. Weighted adverse scores were obtained according to the HR values of the different risk factors: age ≥60 years old (1 point), HCT ≥48% (1 point), at least one CV risk factor (1 point), history of thrombosis (1 points), and V617F% ≥50% (1 points), and the risk model was established. The groups included a lowrisk (0 points), intermediate-risk (1 points), and high-risk group (≥2 points). Using this new risk model of thrombosis, we observed that the incidence of thrombosis was 72.9%, 33.7%, and 9.1% in the high-, intermediate-and low-risk groups, respectively, and was significantly different between each group (P < .0001). The results of thrombosis-free survival analysis showed that patients in the high-risk group (n = 140; average thrombosis-free survival, 5 years; 95% CI 
| DISCUSSION
It has been reported that the incidence of thrombosis in PV, ET, and PMF patients was 5.5, 3.0, and 2.23 per 100 patient-years. [14] [15] [16] Thrombosis-related deaths accounted for 45%, 26%, and 12% of deaths in patients with PV, ET, and PMF [17] [18] [19] ; therefore, thrombosis is considered the most important cause of death and disability of MPN patients, and the study of thrombosis is a consistent topic in the field of MPN.
Multiple studies have shown a clear correlation between different driver mutations (JAK2/CALR/MPL) and thrombosis in MPN patients. [20] [21] [22] For example, PMF patients with JAK2 V617F and MPL W515L/K mutations have a higher risk of thrombosis and worse prognosis than patients with CALR mutations, and CALR type I mutations corresponded to better prognosis than CALR type II mutations. 9, 22 Previous studies have focused on the occurrence of thrombosis in the context of the same disease subtype (PV or ET or PMF), but this study focused on the same gene mutation (JAK2 V617F ) among different subtypes of MPN to study the thrombosis of different diagnoses of MPN, which can exclude the influence of other driver mutations. By studying this particular driver mutation, JAK2 V617F , we can explore the characteristics in MPN patients who have thrombosis and varying clinical characteristics, identify common risk factors for thrombosis in patients with JAK2 V617F -mutated MPN, and provide a theoretical basis for accurately preventing and treating thrombosis in patients with JAK2 V617Fmutated MPN. Our study found that the overall incidence of thrombosis in patients with JAK2 V617F -mutated MPN was 5.82/100 patient-years, which was higher than that in patients with MPN with other driver gene mutations, confirming the importance of the JAK2 V617F mutation in the formation of thrombosis.
Regarding the site of thrombosis, Hultcrantz 23 reported that the incidence of arterial thrombosis in PV and ET patients was approximately 2-3 times higher than that of venous thrombosis, but the incidence of arterial and venous thrombosis in PMF patients was similar. In our study, the incidence of arterial thrombosis (91.4%) in patients with JAK2 V617F -mutated MPN was higher than that observed in Western-based studies. 24 incidence of venous thrombosis (16.6%) is lower, and it is possible that ethnically specific inflammatory cytokines affect coagulation and are related to the different observations by physicians with regard to the latent incidence of venous thrombosis. We further refined the analysis of thrombosis in patients with JAK2 V617F -mutated MPN with different subtypes, and the results show that the risk of thrombosis in PV patients was significantly higher than that in ET and PMF patients. For PV patients, similar to the study by Tefferi A et al, 25 age ≥60 years, history of thrombosis and V617F% ≥50% were risk factors affecting PV thrombosis, especially arterial thrombosis. In PV patients, the incidence of thrombosis in patients with V617F% ≥50% was 4.632 times higher than that in patients with V617F% <50%. Therefore, reducing V617F% during the treatment of PV patients is crucial to prevent thrombosis, especially the occurrence of arterial thrombosis complications. Compared with PV and ET patients, PMF patients had a relatively lower overall incidence of thrombosis, which may be related to the higher progression rate and early mortality of acute leukemia transformation and other diseases in PMF patients. In this study, the high incidence of portal vein and splenic arterial thrombosis in PMF was associated with significant splenomegaly and more complex inflammatory factors, which trigger abnormal coagulation.
HCT and reticular fiber quantity are important indicators for the classification and diagnosis of MPN. Tiziano and Roberto 26 showed that PV patients with 45%-50% HCT had a significantly higher risk of thrombosis than those with controlled HCT at 45%. In our study, the HCT cutoff value that affected thrombosis was 48%. We then found that only 46.1% of patients with HCT ≥45% had thrombosis, whereas 66.5% of patients with HCT ≥48% had thrombosis. Multivariate analysis showed that HCT ≥48% was a risk factor for thrombosis in JAK2 V617Fmutated MPN. Campbell et al 27 showed that with an increase in the number of reticular fibers, the incidence of thrombosis in MPN also increases. In our study, it was found that for patients with JAK2 V617F -mutated MPN, although the incidence of thrombosis increased with the increase in the number of grade 0-2 reticular fibers, the incidence of thrombosis was lower in patients with grade 3 reticular fibers. This may be associated with a higher incidence of acute leukemia transformation and early mortality in patients with a higher number of reticular fibers.
CV risk factors mainly include hypertension, hyperlipidemia, diabetes, and smoking. Our results showed that 55.5% of patients with thrombosis had at least one CV risk factor, and at least one CV risk factors was also a risk factor for thrombosis in Chinese PV patients. Multivariate analysis also demonstrated the importance of CV risk factors. Thus, CV risk factors play an important role in the prognosis of thrombosis in patients with JAK2 V617F -mutated MPN.
This study shows that a history of thrombosis is a risk factor for thrombosis in JAK2 V617F -mutated MPN, whether in PV, ET or PMF. Therefore, in the treatment of patients with JAK2 V617F -mutated MPN, more active measures, such as cytoreductive and anti-atherosclerosis regimens, should be taken for those patients who have experienced thrombosis to prevent the recurrence of thrombosis and improve survival. Tefferi A 14 and Barbui T 12 established the thrombosis prognostic models of PV and ET, respectively, and their results showed that a history of thrombosis is an important risk factor for MPN patients. On the basis of our multivariable analysis, a risk model of Chinese MPN patients with the JAK2 V617F mutation was established based on age ≥60 years old, HCT ≥48%, at least one cardiovascular risk factor, history of thrombosis, and V617F% ≥50%. Furthermore, this model showed that the incidence of thrombosis in the high-risk group was as high as 72.9%, and average thrombosis-free survival was 5 years. Therefore, for high-risk patients, reducing V617F%, controlling HCT and mitigating cardiovascular risk factors are necessary measures to prevent thrombosis in patients with JAK2 V617Fmutated MPN.
In conclusion, the Chinese thrombosis risk model of JAK2 V617F -mutated MPN established in this study suggests that elderly patients with a history of thrombosis should reduce V617F%, control HCT to less than 48% and mitigate cardiovascular risk factors, all of which are necessary measures to prevent thrombosis in patients with JAK2 V617F -mutated MPN. As the application of deep-sequencing technology has advanced the diagnosis and prognosis evaluation of hematologic diseases, our future research direction is to explore the role of different accompanying gene mutations in thrombotic events of patients with JAK2 V617F -mutated MPN and to establish a thrombosis model that includes accompanying mutations.
